![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/26/2904448/0/en/VYNE-Therapeutics-to-Participate-in-Leerink-Partners-Therapeutics-Forum.html
https://www.globenewswire.com/news-release/2024/06/13/2898338/0/en/VYNE-Therapeutics-Announces-Dosing-of-First-Participants-in-Phase-1a-Trial-of-Novel-BD2-Selective-BET-Inhibitor-VYN202.html
https://www.globenewswire.com/news-release/2024/06/05/2893807/0/en/VYNE-Therapeutics-Announces-Dosing-of-First-Subject-in-Phase-2b-Vitiligo-Trial-of-Novel-BET-Inhibitor-VYN201.html
https://www.globenewswire.com/news-release/2024/05/09/2878712/0/en/VYNE-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/06/2875779/0/en/VYNE-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-VYN202-a-Novel-BD2-Selective-BET-Inhibitor.html
https://www.globenewswire.com/news-release/2024/05/01/2873158/0/en/VYNE-Therapeutics-Announces-Oral-Presentations-for-VYN201-at-the-2024-Society-for-Investigative-Dermatology-SID-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/03/19/2848504/0/en/VYNE-Therapeutics-to-Participate-in-the-H-C-Wainwright-2nd-Annual-Autoimmune-Inflammatory-Disease-Virtual-Conference.html
https://www.globenewswire.com//news-release/2024/02/29/2837916/0/en/VYNE-Reports-2023-Fourth-Quarter-and-Year-End-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/02/21/2832694/0/en/VYNE-Therapeutics-to-Participate-in-the-TD-Cowen-44th-Annual-Health-Care-Conference.html